Targets › BCL2L2
2 programs from 2 companies in 10 trials: 8 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2026.
Promotes cell survival. Blocks dexamethasone-induced apoptosis. (UniProt, Q92843)
Open in Phaseline: the race on BCL2L2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AbbVie | Navitoclax Apoptosis regulator Bcl-2 inhibitor; Apoptosis regulator Bcl-X inhibitor; Apoptosis regulator Bcl-W inhibitor | BCL2, BCL2L1, BCL2L2, BCL2L2-PABPN1 | Phase 3 | Myelofibrosis (MF); Myeloproliferative Neoplasm; Mantle Cell Lymphoma Refractory; High Grade Serous Carcinoma … | Dec 2026 |
| Ascentage Pharma Group | APG-1252 BCL-2 family protein inhibitor | BCL2, BCL2L1, BCL2L2, MCL1 | Phase 1 | EGFR Positive Non-small Cell Lung Cancer | – |
Myelofibrosis (MF) (1) Myeloproliferative Neoplasm (1) Mantle Cell Lymphoma Refractory (1) High Grade Serous Carcinoma (1) Myeloid Malignancy (1) Refractory Acute Lymphoblastic Leukemia (1) Recurrent Acute Myeloid Leukemia (1) Metastatic Malignant Solid Neoplasm (1) Clinical Stage III Cutaneous Melanoma AJCC v8 (1) EGFR Positive Non-small Cell Lung Cancer (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.